Pharmacological inhibition of USP18 improves antibacterial responses and the intracellular control of Mycobacterium tuberculosis in macrophages
Our results suggest that the pharmacological inhibition of USP18 can be further explored as a therapeutic tool in the control of tuberculosis.
Authors
- R. Schnell (ORCID: https://orcid.org/0000-0001-7530-3629)
- Paul P. Geurink (ORCID: https://orcid.org/0000-0003-1849-1111)
- Yi Zhong (ORCID: https://orcid.org/0000-0002-0929-8224)
- Stefano Gastaldello (ORCID: https://orcid.org/0000-0001-7369-8452)
- Martin Rottenberg
- Volker Lauschke
- Jianping Xie
- Qiao Zhang
- Zhen Gong
Institutions
- Central South University (CN)
- Southwest University (CN)
- Anhui Medical University (CN)
- Leiden University Medical Center (NL)
- Karolinska Institutet (SE)
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Second Xiangya Hospital of Central South University (CN)
- Zhejiang University (CN)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1739628
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Robert Bosch Stiftung
- Swedish Foundation for International Cooperation in Research and Higher Education
- Karolinska Institutet
- Vetenskapsrådet